SCHEMBL3563493

SCHEMBL3563493

CCc1ccc(S(=O)(=O)Nc2ccccc2CCCc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 5/20 0.63
METAP2 P50579 4/20 0.51
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
NCOR2 Q9Y618 1/20 0.50
LIMK2 P53671 1/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
KMT2A Q03164 1/20 0.48
TAS2R14 Q9NYV8 1/20 0.48
POLB P06746 1/20 0.48
TSHR P16473 1/20 0.48
KDM4E B2RXH2 1/20 0.46
ACLY P53396 1/20 0.46
PTGER1 P34995 1/20 0.46
PTGER4 P35408 1/20 0.46
PTGER3 P43115 1/20 0.46
PTGER2 P43116 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3564319 0.93 SLC16A3 (0.63) SLC16A3METAP2HDAC3HDAC1NCOR2
SCHEMBL3561760 0.93 SLC16A3 (0.63) SLC16A3METAP2HDAC3HDAC1NCOR2
SCHEMBL3556734 0.93 SLC16A3 (0.72) SLC16A3METAP2HDAC3HDAC1NCOR2
SCHEMBL3557081 0.92 SLC16A3 (0.66) SLC16A3METAP2HDAC3HDAC1NCOR2
SCHEMBL3554675 0.91 SLC16A3 (0.63) SLC16A3METAP2HDAC3HDAC1NCOR2
SCHEMBL3559581 0.91 SLC16A3 (0.63) SLC16A3METAP2HDAC3HDAC1NCOR2
SCHEMBL3561633 0.90 SLC16A3 (0.64) SLC16A3METAP2HDAC3HDAC1NCOR2
SCHEMBL3554625 0.89 SLC16A3 (0.69) SLC16A3METAP2MEN1KMT2ATSHR
SCHEMBL3559576 0.89 SLC16A3 (0.69) SLC16A3METAP2HDAC3HDAC1NCOR2
SCHEMBL3556182 0.89 SLC16A3 (0.68) SLC16A3METAP2HDAC3HDAC1NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 SLC16A3 425/4885METAP2 2438/4885HDAC3 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.